SEC Form 4 · accession 0000899243-18-006982
BIODELIVERY SCIENCES INTERNATIONAL INC · BDSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francis E Odonnell Jr.
Director
Period of report
Mar 7, 2018
Accepted (ET)
Mar 9, 2018 · 6:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001103021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 7, 2018 | M | 48,418 | $0.00 | A | 319,717 | D | |
| Common StockF2 | Mar 7, 2018 | M | 46,000 | $0.00 | A | 365,717 | D | |
| Common StockF4 | Mar 7, 2018 | S | 47,210 | $2.13 | D | 318,507 | D | |
| Common StockF5 | Mar 8, 2018 | M | 133,333 | $0.00 | A | 451,840 | D | |
| Common StockF6 | Mar 8, 2018 | S | 66,666 | $2.14 | D | 385,174 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | $0.00 | Mar 7, 2018 | M | 48,418 | D | Mar 7, 2018 | Mar 7, 2018 | Common Stock | 48,418 | 0 | D |
| Restricted Stock Units | $0.00 | Mar 7, 2018 | M | 46,000 | D | Mar 7, 2018 | Mar 1, 2019 | Common Stock | 46,000 | 92,000 | D |
| Restricted Stock Units | $0.00 | Mar 8, 2018 | M | 133,333 | D | Mar 8, 2018 | Sep 12, 2018 | Common Stock | 133,333 | 133,333 | D |
Explanation of responses
- F1The shares of common stock were acquired by the Reporting Person as a result of the vesting of 48,418 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 7, 2018.
- F2The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (i) September 13, 2018 and (ii) March 1, 2019.
- F3The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
- F4On March 7, 2018, the Reporting Person sold an aggregate of 47,210 shares of the Issuer's Common Stock at a weighted average price of $2.13 per share. The highest sale price for the Common Stock was $2.20 per share and the lowest sale price was $2.10 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on March 8, 2018. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on September 12, 2018.
- F6On March 8, 2018, the Reporting Person sold an aggregate of 66,666 shares of the Issuer's Common Stock at a weighted average price of $2.14 per share. The highest sale price for the Common Stock was $2.18 per share and the lowest sale price was $2.10 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.